LETTER TO JMG

Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M *MECP2* mutation, and the direction and degree of skewing of X-chromosome inactivation

Hayley Archer, Julie Evans, Helen Leonard, Lyn Colvin, David Ravine, John Christodoulou, Sarah Williamson, Tony Charman, Mark E S Bailey, Julian Sampson, Nicholas de Klerk, Angus Clarke

....

Introduction: Rett syndrome (RTT) is an X-linked dominant neurodevelopmental disorder that is usually associated with mutations in the *MECP2* gene. The most common mutations in the gene are p.R168X and p.T158M. The influence of X-chromosome inactivation (XCI) on clinical severity in patients with RTT with these mutations was investigated, taking into account the extent and direction of skewing.

Methods: Female patients and their parents were recruited from the UK and Australia. Clinical severity was measured by the Pineda Severity and Kerr profile scores. The degree of XCI and its direction relative to the X chromosome parent of origin were measured in DNA prepared from peripheral blood leucocytes, and allele-specific polymerase chain reaction was used to determine the parental origin of mutation. Combining these, the percentage of cells expected to express the mutant allele was calculated.

Results: Linear regression analysis was undertaken for fully informative cases with p.R168X (n = 23) and p.T158M (n = 20) mutations. A statistically significant increase in clinical severity with increase in the proportion of active mutated allele was shown for both the p.R168X and p.T158M mutations.

Conclusions: XCI may vary in neurological and haematological tissues. However, these data are the first to show a relationship between the degree and direction of XCI in leucocytes and clinical severity in RTT, although the clinical utility of this in giving a prognosis for individual patients is unclear.

R ett syndrome (RTT) is an X-linked dominant neurodevelopmental disorder, usually caused by mutations in the methyl-CpG-binding protein 2 (*MECP2*, OMIM#300005) gene. Mutations often arise at CpG hotspots,[1] and the most common mutations in *MECP2* found in RTT cases are p.T158M and p.R168X (RettBASE, http://mecp2.chw.edu.au/). RTT has a wide clinical variability in terms of its severity.[2] Studies investigating the association between genotype and phenotype were originally quite inconsistent in their findings. However, with larger studies and increasing numbers of publications, evidence for definite relationships between genotype and phenotype is becoming clearer.[3] Apparent differences in study results often occurred because of the use of different means of classifying and recording clinical severity. Additionally, the effects of X-chromosome inactivation (XCI) status and other epigenetic influences on *MECP2* function are likely to have a real influence on the variation in phenotype associated with specific mutations.

XCI occurs early in embryogenesis at the blastula stage, and is usually a random process.[4 5] The inactive X chromosome is determined as cells become pluripotent; once this has happened, lineages derived from each of these cells will all have the same X chromosome inactivated through a process of methylation. Some studies have shown that there is an increased tendency for skewing of XCI in lymphocytes in RTT when compared with age-matched controls, and that this usually confers a protective effect.[6–8] The most striking clinical examples of the effects of XCI in RTT are seen in twins with disparate severity[9 10] and in healthy carrier mothers with skewed XCI (presumed favourable) with affected daughters.[11–15]

In this study, we adopted a new approach to investigate genotype–phenotype relationships in RTT by exploring the association between clinical severity and the proportion of active mutated allele for the two common *MECP2* mutations, p.R168X and p.T158M.

METHODS

Data sources

Patients were recruited from three sources in two countries (table 1): UK cases from two RTT research studies (Cardiff and Glasgow) and Australian cases from the Australian Rett Syndrome Database (www.ichr.uwa.edu.au/rett/aussierett/).

UK patients were recruited from those referred to Cardiff for molecular genetic analysis, or were selected from those participating in a large genotype–phenotype study.[2] Cardiff provides one of the two main diagnostic molecular testing services within the UK. By July 2005, 245 patients had a *MECP2* mutation identified and all were invited to participate in the Cardiff Rett Study. DNA samples were already available from the proband, and a blood sample was obtained from at least one parent where this was not already available. In total, samples were available from 18 of 25 Cardiff cases with p.T158M and 28 of 37 cases with p.R168X. An additional seven p.T158M cases and three p.R168X cases were obtained from Scotland (the majority identified in Glasgow).[2]

The Australian Rett Syndrome Database is an ongoing population-based registry, established in 1993, of Australian RTT cases born since 1976. Data are collected from families and clinicians on enrolment and, in combination with molecular

....

Abbreviations: PCR, polymerase chain reaction; RTT, Rett syndrome; SNP, single-nucleotide polymorphism; 3′UTR, 3′ untranslated region; XCI, X-chromosome inactivation

Table 1 Distribution of sample sources and informative data for mutations p.T158M and p.R168X

Source	Cases (n)	Informative and clinical data available
T158M		
Cardiff	18	8
Scotland	7	3
Australia	15	9
Total	40	20
R168X		
Cardiff	28	15
Scotland	3	2
Australia	12	6
Total	43	23
Total	83	43

data, evaluated for compliance with the RTT diagnostic criteria.[16] By July 2005, mutation testing had been carried out in 254 (88.2%) of the 288 cases, with a pathogenic *MECP2* mutation detected in 186 (73.2%). DNA samples from probands that had at least one parental sample available were accessible for testing in 15 of 21 cases of p.T158M and in 12 of 21 cases of p.R168X.

XCI studies

Determination of degree and direction of X-inactivation status

XCI was determined using a modified standard method.[17] Separate aliquots of DNA were predigested with the methylation-sensitive enzymes *Hpa*II and McrBC (New England Biolabs, Hitchin, Hertfordshire, UK). The triplet repeat at the *HUMARA* locus was then amplified by polymerase chain reaction (PCR) using fluorescent primers, and analysed using an ABI 3100 automated sequencer and Genotyper software (Applied Biosystems, Foster City, California, USA). Allele peak areas were compared for *Hpa*II digested, McrBC digested and undigested DNA to determine the degree of XCI. *Hpa*II predigestion will prevent PCR amplification of the *HUMARA* allele on the unmethylated (active) X chromosome; conversely, McrBC predigestion will prevent PCR amplification of the allele on the methylated (inactive) X chromosome. This allows identification of the allele that is present on the more active X chromosome. DNA samples from the parents were genotyped to determine the parental origin of the alleles, and thereby from which parent the more active X chromosome was inherited.

Determination of the parental origin of the mutation

Intron 3 and the 3′ untranslated region (3′UTR) of *MECP2* were sequenced in the patients to find informative single-nucleotide polymorphisms (SNPs). When an SNP was found, allele-specific PCR primers were designed so that the base on the 3′ end of each primer was complementary to only one allele of the SNP (table 2). SNPs are numbered relative to the position of the stop codon ($+878C{\to}G$) or the end of exon 3 ($+266C{\to}T$, $+516C{\to}T$ and $+648A{\to}G$). All SNPs are available in dbSNP (http://www.ncbi.nlm.nih.gov/SNP): $+878C{\to}G$ = rs3027924, $+266C{\to}T$ = rs2075596, $+516C{\to}T$ = rs3027931 and $648A{\to}G$ = rs3850326.

Allele-specific PCR was performed to amplify a fragment including the position of the mutation. The allele-specific PCR products were sequenced to determine which haplotype contained the mutation. It was then possible to determine the

parent of origin by genotyping the SNP in the parents. By combining the parent of origin with the XCI results, the percentage of cells expected to be expressing the mutant *MECP2* was calculated. Where parent of origin could not be determined, but it was known from which parent the more active X chromosome was inherited, it was assumed that the mutation was of paternal origin.

Phenotype scoring, data management and statistical analysis

Genotype–phenotype investigations by our groups have until now relied on scoring systems previously established by others. These scales use simple and objective measures that are not dependent on clinical skill or intuition. We refer to these scoring systems as the Kerr profile and the Pineda and Percy scores.[18] As our previous work has shown that the Pineda score, which takes into account historical data as well as current clinical status, is the most sensitive to change, we used both the Kerr profile and Pineda Severity scores. These scores had already been generated for the Australian cases based on data collected in 2000.[18 19] For the UK cases, when necessary, telephone interviews were arranged with families (conducted by HA) to obtain the necessary information and to supplement the details available from clinical sources.

Statistical analysis was undertaken using Stata V.9.0. For the 15 Australian cases the previously generated scores, where missing data were replaced with the average score for that item for the Rett classification type (ie, classic, mild atypical or early-onset atypical), were used.[18] For the 28 UK cases, an imputation routine, in which missing values for each scale were imputed on the basis of other values in that scale, was used to estimate missing values and to maximise the use of the scarce data.[20] For this, imputation data that had been collected on a further 102 UK cases (either with p.T158M or p.R168X mutations but non-informative XCI data, or with another mutation) were included. Linear regression was undertaken with the Kerr profile and Pineda scales as continuous variables and the percentage of the mutant allele as the independent variable. A case with both p.R168X and trisomy 21 was excluded from the analysis to avoid the potential confounding effects arising from coexisting Down's syndrome.[21]

RESULTS

Molecular assay

Of the 83 cases recruited, XCI analysis failed in 17 cases due to poor DNA quality or insufficient DNA. Of the remaining 66 cases, 9 were homozygotic at the androgen receptor locus, and in 14 cases it was not possible to ascertain which parental allele was most active because of missing paternal samples or an approximate 50:50 ratio of XCI. Among these non-contributory samples, two mutations were of maternal origin and three of paternal origin. In the 43 cases in which the most active allele was ascertained, 21 mutations were of paternal origin and none were of maternal origin. The normal allele was favoured in 18 of 21 (86%) cases. In the other 22 cases there were no informative SNPs to allow determination of parental origin.

Clinical data

For the 28 UK cases there were 29 missing individual items, equivalent to 5.2% of all items, for the Kerr profile and 26 missing items, equivalent to 9.3% of all items, for the Pineda scale. In the Kerr profile items relating to height, joint contractures, mood and sleep disturbance, and in the Pineda scale, items relating to age at sitting and acquisition and loss of ambulation, had the most missing items.

Table 2 Primers used for allele-specific polymerase chain reaction

| Primer location	Primer sequence
3'UTR sequencing primers	
UTR-F	5'-gcaaggagagcagccccaagg-3'
UTR-R	5'-agttctcaacactgtcacatc-3'
3'UTR allele-specific primers (+878C→G; use with EX4-F or IVS3-2F primer)	
878C	5'-ccctgtccactaagtcacag-3'
878G	5'-ccctgtccactaagtcacac-3'
Intron 3 sequencing primers	
IVS3-F	5'-aagttctcaaggtagcag-3'
IVS3-R	5'-aggaacaattagaggctc-3'
Intron 3 allele-specific primers (+266C→T)	
266C	5'-gcagaggaacttgcagagcc-3'
266T	5'-gcagaggaacttgcagagct-3'
Intron 3 allele-specific primers (+516C→T)	
516C	5'-atgggcctcagcctgacaac-3'
516T	5'-atgggcctcagcctgacaat-3'
Intron 3 allele-specific primers (+648A→G)	
648A	5'-gcagtgtgactctcgttcaa-3'
648G	5'-gcagtgtgactctcgttcag-3'
Common reverse primer for intron 3 ASP	
EX4-R	5'-tgagtcttagctggctccttg-3'
Extra sequencing primers	
IVS3-2F	5'-gagcctctaattgttccttg-3'
EX4-F	5'-tccacccaggtcatggtgatc-3'

Figure1 Correlation between proportion of R168X allele active and clinical severity. $R^2 = 17\%$.

been shown to account for 19% of the variance in phenotypic outcome, a substantial effect.

DISCUSSION

In this collaborative international study, our data show a relationship between the extent and direction of skewing of XCI and clinical severity for cases with the p.T158M or p.R168X mutation in the *MECP2* gene. Both p.R168X and p.T158M are typically associated with a severe presentation,[2 7 19] but both have also been reported in mildly affected cases with the preserved speech variant of RTT.[22–24] This suggests that the clinical variability associated with these mutations is broad, and that this may be due to the role of epigenetic influences, including XCI. This contrasts with those with the p.R133C mutation (usually mildly affected)[25] or those with the p.R255X mutation (usually more severely affected),[26] where there is less variability in terms of severity. The sensitivity of the available severity scales may not be great enough to detect subtle differences caused by the effects of XCI status.

An RNA-based approach to determine the parent of origin would have resulted in a higher ascertainment, but was not possible in this study as fresh patient samples were not available for RNA extraction. The method used to determine XCI status and parental origin of the mutation in this study was straightforward and did not require further fresh blood samples from patients. However, there were losses at each stage of the testing process. The androgen receptor assay is usually uninformative in approximately 20–30% of cases,[7 27] although

Correlation between proportion of mutated allele activity and clinical severity

Among cases with the p.R168X mutation, clinical severity increased significantly as the proportion of cells with an active mutant allele increased (fig 1, table 3). This effect was observed with both the Pineda ($p = 0.05$) and Kerr ($p = 0.014$) scoring systems. When the data were adjusted for age, the effect with the Kerr profile became more significant ($p = 0.005$) and the Pineda score less so ($p = 0.15$).

As the proportion of cells with an active mutant allele increased in cases with the p.T158M mutation, the Pineda score increased significantly ($p = 0.04$), again indicating greater severity (fig 2, table 3), but the correlation was not significant in the case of the Kerr profile score. The magnitude of the association was the same as with the p.R168X mutation, both with and without age adjustment.

For both mutations, repeating the analysis using the logistic transformation of the percentage of the mutant allele active had minimal effect on the results. In our dataset, these two mutations have very similar Kerr and Pineda scores, indicating that on average they are of similar severity. Therefore, we also assessed the effect of X inactivation on the two groups combined. This has shown that the increasing severity indicated by both the Pineda and the Kerr scales was associated with the effects of X inactivation both when not adjusted ($p = 0.003$ for either scale) and when adjusted for age ($p = 0.005$ for Pineda and $p = 0.001$ for Kerr), as well as with the direction of XCI skewing. The R^2 (square of the correlation coefficient) was 19% for both; the direction of XCI has therefore

Figure 2 Correlation between proportion of T158M allele active and clinical severity. $R^2 = 20\%$.

Table 3 Relationship between phenotype severity scores and percentage of mutant allele active for mutations p.T158M and p.R168X

Mutation	Scoring system	Cases (n)	Mean (SD)	Minimum value	Maximum value	r	*Reg. coefft.	p Value
p.R168X	Pineda scale unadjusted	23	16.87 (3.29)	10.93	21.69	0.42	0.11	0.05
	Pineda scale age adjusted						0.08	0.15
p.R168X	Kerr profile unadjusted	23	22.65 (4.40)	14.25	30	0.49	0.16	0.02
	Kerr profile age adjusted						0.21	0.005
p.T158M	Pineda scale unadjusted	20	17.64 (4.78)	9.68	25	0.45	0.16	0.05
	Pineda scale age adjusted						0.17	0.04
p.T158M	Kerr profile unadjusted	20	24.90 (6.93)	10	33	0.35	0.17	0.13
	Kerr profile age adjusted						0.20	0.09
p.T158M and p.R168X	Pineda scale unadjusted	43	17.48 (4.17)	9.68	25	0.44	0.13	0.003
	Pineda scale age adjusted						0.12	0.005
p.T158M and p.R168X	Kerr profile unadjusted	43	23.70 (5.76)	10	33	0.44	0.17	0.003
	Kerr profile age adjusted						0.20	0.001

*Coefficient of the regression of severity score on percentage of mutant allele active—represents the increase in severity score for each percentage point increase.

in our experience this was true for 9 of 66 (15%) cases with DNA of suitable quantity and quality for analysis. Further cases (14/66, 21%) in this study were lost because of difficulty in ascertaining the most active parental allele, usually in cases where only one parental sample was available. In samples where we could determine the parental origin of the MECP2 mutation, 92% (24/26) were of paternal origin, as found in previous studies.[28 29] Paternal origin of mutation was assumed in 51% (22/43) of cases included in the investigation, so it is likely that a small number of these cases had the incorrect allele assigned as the active one. It is interesting that so few cases were identified in which >60% of the mutant MECP2 allele was active. There might be a selective advantage in growth and cell division for those haematopoietic cells using the X chromosome with the intact MECP2 locus, but this is not confirmed. There may also be some selection against the long-term survival of females, with >60% of their cells using the altered copy of the MECP2 locus, or their phenotype may be less typical of classic RTT and may more closely resemble the encephalopathy of males, with MECP2 mutations associated in females with classic RTT. In either case, they might be under-represented in our clinically selected group. An additional part of the explanation may lie in the fact that, where there is skewing of XCI, it is usually the paternal X chromosome that is preferentially inactivated, and, combined with the fact that most mutations are paternal, this leads to the conclusion that the cases that are more heavily skewed are less likely to express the mutant copy of MECP2.[8]

In this study, we found that XCI almost always favours the normal allele, as has been reported in mouse models of RTT,[30 31] and this is the pattern commonly seen in other X-linked diseases.[32] Although making assumptions based on XCI status in lymphocytes might be considered a compromise in this study, it was neither realistic nor ethical to obtain neurological tissues from patients to study the effects of direction of skewing. Although we have shown that there is a relationship between severity and XCI by mutation, it should not be surprising that there was still variability in those with the same mutation and the same proportion of active mutant allele. In this situation, each individual might be expected to have differences in inter-tissue and intra-tissue XCI status, as is sometimes observed in mouse models.[30 33] This confirms the finding that milder cases of RTT have a greater degree of XCI skewing than more severe cases, although the parent of origin of the mutation was not determined in that study.[8] The variability in the pattern of XCI is likely to be of particular importance in the brain, where abnormal expression of MECP2 in a neurone will affect the expression of MECP2 in the surrounding neurones, even if they are expressing the normal

allele.[34] Although XCI clearly affects clinical severity in RTT, assessment of XCI status is unlikely to be useful as a prognosticator for individual cases, with the possible exception of those with extreme skewing.

There are now a small number of other examples where influences other than XCI may be modulating phenotype in RTT. We might expect any male patient to represent the most severe phenotype associated with a particular mutation. There is a published report of a male patient with an early truncating mutation, which would be expected to be associated with a severe phenotype, yet he was relatively mildly affected at 11 years.[35] There was no evidence for somatic mosaicism, although this could not be completely ruled out. This example suggests that there may be other background genetic and epigenetic influences that contribute significantly to the clinical manifestations of RTT, but the exact nature of these additional factors is yet to be determined.

Despite the limitations, we were able to show in DNA extracted from peripheral leucocytes that there was a correlation between the proportion of the mutated allele used by an individual and the clinical severity of a predominantly neurodevelopmental phenotype. Combining the efforts of three countries was essential for this study, but wider collaborative efforts will be required to study the phenotype associated with other common mutations in a similar way. We had hoped to look at the effects of the parent of origin based on the suggestion that this may also modulate the phenotype.[36] As mutations of maternal origin are infrequent, substantially greater numbers of patients would be required to deal with this question.

. . . .

Authors' affiliations
Hayley Archer*, Julie Evans*, Julian Sampson, Angus Clarke, Institute of Medical Genetics, Cardiff University, University Hospital of Wales, Cardiff, UK
Helen Leonard, Lyn Colvin, Nicholas de Klerk, Telethon Institute of Child Health Research, Centre for Child Health Research, The University of Western Australia, Perth, Western Australia, Australia
David Ravine, Western Australian Institute of Medical Research, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia
John Christodoulou, Sarah Williamson, Western Sydney Genetics Program, The Children's Hospital at Westmead and Discipline of

Paediatrics and Child Health, University of Sydney, Sydney, New South Wales, Australia

Tony Charman, Behavioural & Brain Sciences Unit, Institute of Child Health, University College London, London, UK

Mark E S Bailey, Division of Molecular Genetics, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, UK

*These authors contributed equally to the work.

REFERENCES

1 **Amir RE**, Van dV I, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat Genet* 1999;**23**:185–8.
2 **Charman T**, Neilson TC, Mash V, Archer H, Gardiner MT, Knudsen GP, McDonnell A, Perry J, Whatley SD, Bunyan DJ, Ravn K, Mount RH, Hastings RP, Hulten M, Orstavik KH, Reilly S, Cass H, Clarke A, Kerr AM, Bailey MES. Dimensional phenotypic analysis and functional categorisation of mutations reveal novel genotype-phenotype associations in Rett syndrome. *Eur J Hum Genet* 2005;**13**:1121–30.
3 **Ham AL**, Kumar A, Deeter R, Schanen NC. Does genotype predict phenotype in Rett syndrome? *J Child Neurol* 2005;**20**:768–78.
4 **Gartler SM**, Dyer KA, Graves JA, Rocchi M. A two step model for mammalian X-chromosome inactivation. *Prog Clin Biol Res* 1985;**198**:223–35.
5 **Lyon MF**. X-chromosome inactivation as a system of gene dosage compensation to regulate gene expression. *Prog Nucleic Acid Res Mol Biol*, 1989;**36**:119–30.
6 **Weaving LS**, Williamson SL, Bennetts B, Davis M, Ellaway CJ, Leonard H, Thong MK, Delatycki M, Thompson EM, Laing N, Christodoulou J. Effects of MECP2 mutation type, location and X-inactivation in modulating Rett syndrome phenotype. *Am J Med Genet* 2003;**118A**:103–14.
7 **Fukuda T**, Yamashita Y, Nagamitsu S, Miyamoto K, Jin JJ, Ohmori I, Ohtsuka Y, Kuwajima K, Endo S, Iwai T, Yamagata H, Tabara Y, Miki T, Matsuishi T, Kondo I. Methyl-CpG binding protein 2 gene (MECP2) variations in Japanese patients with Rett syndrome: pathological mutations and polymorphisms. *Brain Dev* 2005;**27**:211–17.
8 **Knudsen GPS**, Neilson TCS, Pedersen J, Kerr A, Schwartz M, Hulten M, Bailey MES, Orstavik KH. Increased skewing of X chromosome inactivation in Rett syndrome patients and their mothers. *Eur J Hum Genet* 2006;**14**(11):1189–94.
9 **Ishii T**, Makita Y, Ogawa A, Amamiya S, Yamamoto M, Miyamoto A, Oki J. The role of different X-inactivation pattern on the variable clinical phenotype with Rett syndrome. *Brain Dev* 2001;**23**(Suppl 1):S161–4.
10 **Gill H**, Cheadle JP, Maynard J, Fleming N, Whatley S, Cranston T, Thompson EM, Leonard H, Davis M, Christodoulou J, Skjeldal O, Hanefeld F, Kerr A, Tandy A, Ravine D, Clarke A. Mutation analysis in the MECP2 gene and genetic counselling for Rett syndrome. *J Med Genet* 2003;**40**:380–4.
11 **Wan M**, Lee SS, Zhang X, Houwink-Manville I, Song HR, Amir RE, Budden S, Naidu S, Pereira JL, Lo IF, Zoghbi HY, Schanen NC, Francke U. Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. *Am J Hum Genet* 1999;**65**:1520–9.
12 **Bienvenu T**, Carrie A, De Roux N, Vinet MC, Jonveaux P, Couvert P, Villard L, Arzimanoglou A, Beldjord C, Fontes M, Tardieu M, Chelly J. MECP2 mutations account for most cases of typical forms of Rett syndrome. *Hum Mol Genet* 2000;**9**:1377–84.
13 **Obata K**, Matsuishi T, Yamashita Y, Fukuda T, Kuwajima K, Horiuchi I, Nagamitsu S, Iwanaga R, Kimura A, Omori I, Endo S, Mori K, Kondo I. Mutation analysis of the methyl-CpG binding protein 2 gene (MECP2) in patients with Rett syndrome. *J Med Genet* 2000;**37**:608–10.
14 **Hoffbuhr KC**, Moses LM, Jerdonek MA, Naidu S, Hoffman EP. Associations between MeCP2 mutations, X-chromosome inactivation, and phenotype. *Ment Retard Dev Disabil Res Rev* 2002;**8**:99–105.
15 **Villard L**, Levy N, Xiang F, Kpebe A, Labelle V, Chevillard C, Zhang Z, Schwartz CE, Tardieu M, Chelly J, Anvret M, Fontes M. Segregation of a totally skewed pattern of X chromosome inactivation in four familial cases of Rett syndrome without MECP2 mutation: implications for the disease. *J Med Genet* 2001;**38**:435–42.
16 **Laurvick C**, De Klerk N. Bower C, Christodoulou J, Ravine D, Ellaway C, Williamson S, Leonard H. Rett syndrome in Australia: a review of the epidemiology. *J Pediatr* 2006;**148**:347–52.
17 **Allen RC**, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. *Am J Hum Genet* 1992;**51**:1229–39.
18 **Colvin L**, Fyfe S, Leonard S, Schiavello T, Ellaway C, de Klerk N, Christodoulou J, Msall M, Leonard H. Describing the phenotype in Rett syndrome using a population database. *Arch Dis Child* 2003;**88**:38–43.
19 **Colvin L**, Leonard H, de Klerk N, Davis M, Weaving L, Williamson S, Christodoulou J. Refining the phenotype of common mutations in Rett syndrome. *J Med Genet* 2004;**41**:25–30.
20 **Little RJA**, Rubin DB. *Statistical analysis with missing data*, 2nd edn. Hoboken, NJ: Wiley, 2002.
21 **Leonard H**, Weaving L, Eastaugh P, Smith L, Delatycki M, Witt EI, Christodoulou J. Trisomy 21 and Rett syndrome: a double burden. *J Paediatr Child Health* 2004;**40**:406–9.
22 **Huppke P**, Laccone F, Kramer N, Engel W, Hanefeld F. Rett syndrome: analysis of MECP2 and clinical characterization of 31 patients. *Hum Mol Genet* 2000;**9**:1369–75.
23 **Zappella M**, Meloni I, Longo I, Hayek G, Renieri A. Preserved speech variants of the Rett syndrome: molecular and clinical analysis. *Am J Med Genet* 2001;**104**:14–22.
24 **Kerr AM**, Archer HL, Evans JC, Prescott RJ, Gibbon F. People with MECP2 mutation positive Rett disorder who converse. *J Intellect Disabil Res* 2006;**50**:386–94.
25 **Leonard H**, Colvin L, Christodoulou J, Schiavello T, Williamson S, Davis M, Ravine D, Fyfe S, de Klerk N, Matsuishi T, Kondo I, Clarke A, Hackwell S, Yamashita Y. Patients with the R133C mutation: is their phenotype different from patients with Rett syndrome with other mutations? *J Med Genet* 2003;**40**:e52.
26 **Jian L**, Archer HL, Ravine D, Kerr A, de Klerk N, Christodoulou J, Bailey ME, Laurvick C, Leonard H. p.R270X MECP2 mutation and mortality in Rett syndrome. *Eur J Hum Genet* 2005;**13**:1235–8.
27 **Amir RE**, Van dV, I, Schultz R, Malicki DM, Tran CQ, Dahle EJ, Philippi A, Timar L, Percy AK, Motil KJ, Lichtarge O, Smith EO, Glaze DG, Zoghbi HY. Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. *Ann Neurol* 2000;**47**:670–9.
28 **Trappe R**, Laccone F, Cobilanschi J, Meins M, Huppke P, Hanefeld F, Engel W. MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. *Am J Hum Genet* 2001;**68**:1093–101.
29 **Girard M**, Couvert P, Carrie A, Tardieu M, Chelly J, Beldjord C, Bienvenu T. Parental origin of de novo MECP2 mutations in Rett syndrome. *Eur J Hum Genet* 2001;**9**:231–6.
30 **Young JI**, Zoghbi HY. X-chromosome inactivation patterns are unbalanced and affect the phenotypic outcome in a mouse model of Rett syndrome. *Am J Hum Genet* 2004;**74**:511–20.
31 **Watson CM**, Pelka GJ, Radziewic T, Shahbazian MD, Christodoulou J, Williamson SL, Tam PP. Reduced proportion of Purkinje cells expressing paternally derived mutant Mecp2308 allele in female mouse cerebellum is not due to a skewed primary pattern of X-chromosome inactivation. *Hum Mol Genet* 2005;**14**:1851–61.
32 **Azofeifa J**, Voit T, Hubner C, Cremer M. X-chromosome methylation in manifesting and healthy carriers of dystrophinopathies: concordance of activation ratios among first degree female relatives and skewed inactivation as cause of the affected phenotypes. *Hum Genet* 1995;**96**:167–76.
33 **Gibson JH**, Williamson SL, Arbuckle S, Christodoulou J. X chromosome inactivation patterns in brain in Rett syndrome: implications for the disease phenotype. *Brain Dev* 2005;**27**:266–70.
34 **Braunschweig D**, Simcox T, Samaco RC, LaSalle JM. X-chromosome inactivation ratios affect wild-type MeCP2 expression within mosaic Rett syndrome and Mecp2−/+ mouse brain. *Hum Mol Genet* 2004;**13**:1275–86.
35 **Ravn K**, Nielsen JB, Uldall P, Hansen FJ, Schwartz M. No correlation between phenotype and genotype in boys with a truncating MECP2 mutation. *J Med Genet* 2003;**40**:e5.
36 **Pelka GJ**, Watson CM, Christodoulou J, Tam PP. Distinct expression profiles of Mecp2 transcripts with different lengths of 3′UTR in the brain and visceral organs during mouse development. *Genomics* 2005;**85**:441–52.